The University of Chicago Header Logo

Connection

Walter M. Stadler to Imatinib Mesylate

Back to Details
This is a "connection" page, showing publications Walter M. Stadler has written about Imatinib Mesylate.
Walter M. Stadler
Connection Strength
0.065
Imatinib Mesylate
  1. Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial. Clin Genitourin Cancer. 2006 Mar; 4(4):275-80.
    View in: PubMed
    Score: 0.065
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.